ST3GAL3

CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase · Q11203 · ST3GAL3 on Sugi Atlas →

974 patent compounds predicted against ST3GAL3, 759 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15978374	0.76	2/20
SCHEMBL8324407	0.61	2/20
SCHEMBL8322299	0.60	2/20
SCHEMBL8327871	0.59	2/20
SCHEMBL9854621	0.36	2/20
SCHEMBL8148354	0.36	2/20
SCHEMBL9854657	0.35	2/20
Strongylin A (SCHEMBL8273902)	0.35	2/20
SCHEMBL9854637	0.31	2/20
SCHEMBL9854641	0.31	2/20
Lagochiline (SCHEMBL9854633)	0.31	2/20
Lagochiline (SCHEMBL9854640)	0.31	2/20
Lagochiline (SCHEMBL14029530)	0.31	2/20
Epigalocatechin Gallate (SCHEMBL35258)	1.00	1/20
Gallocatechin Gallate (SCHEMBL49461)	1.00	1/20
Epigalocatechin Gallate (SCHEMBL161547)	1.00	1/20
Epigalocatechin Gallate (SCHEMBL1853219)	1.00	1/20
Epigalocatechin Gallate (SCHEMBL8426376)	1.00	1/20
Epigalocatechin Gallate (SCHEMBL10198783)	1.00	1/20
Epigalocatechin Gallate (SCHEMBL13624466)	1.00	1/20

Clinical trials — most relevant to ST3GAL3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease	PHASE4	COMPLETED
A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis	PHASE3	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity	PHASE2	COMPLETED
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Vaccine Treatment for Advanced Malignant Melanoma	PHASE1/PHASE2	COMPLETED
An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy	PHASE2	COMPLETED
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)	PHASE1/PHASE2	UNKNOWN
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Phase I Clinical Study of Chondroitin Sulfate for Treatment of NEC	PHASE1	WITHDRAWN
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
The Natural History of Sialidosis Type I	nan	RECRUITING
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption	nan	UNKNOWN
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
Histoblood Group Antigens as a Risk Factor of Asthma	nan	COMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Registry Gangliosidoses	nan	UNKNOWN
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency	nan	COMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Canadian Fabry Disease Initiative (CFDI) National Registry	nan	RECRUITING
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis	nan	COMPLETED
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children	nan	RECRUITING
Mucin Glycosylating Enzymes in Head and Neck Cancers	nan	UNKNOWN
Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ST3GAL3 binder may also engage these)

Protein	Name	Similarity
P61132	—	1.000	P61132 →
Q02734	—	1.000	Q02734 →
P97325	—	1.000	P97325 →
Q6KB54	—	0.998	Q6KB54 →
Q9Y274	—	0.997	Q9Y274 →
Q11206	—	0.997	Q11206 →
P61130	—	0.995	P61130 →
Q08E15	—	0.993	Q08E15 →
P61131	—	0.992	P61131 →
Q70D51	—	0.992	Q70D51 →
Q64685	—	0.992	Q64685 →
Q91Y74	—	0.992	Q91Y74 →
Q02745	—	0.992	Q02745 →
P70277	—	0.992	P70277 →
ST3GAL1	CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1	0.992	landscape →
P61943	—	0.992	P61943 →
Q8VIB3	—	0.992	Q8VIB3 →
Q8RY00	—	0.991	Q8RY00 →
Q6KB59	—	0.991	Q6KB59 →
ST6GAL1	Beta-galactoside alpha-2,6-sialyltransferase 1	0.991	landscape →
Q6H8M7	—	0.991	Q6H8M7 →
Q6KB55	—	0.991	Q6KB55 →
Q92183	—	0.990	Q92183 →
Q5RE85	—	0.989	Q5RE85 →
Q701R0	—	0.989	Q701R0 →
Q8NDV1	—	0.989	Q8NDV1 →
Q701R2	—	0.989	Q701R2 →
Q64686	—	0.989	Q64686 →
Q68G12	—	0.988	Q68G12 →
Q9SGD2	—	0.988	Q9SGD2 →